GENERIC NAME AVAILABLE AS SODIUM CHANNEL BLOCKERS Disopyramide Generic, Norpace, Norpace CR Flecainide Generic, Tambocor Lidocaine Generic, Xylocaine Mexiletine Generic, Mexitil Procainamide Generic, Pronestyl, Procan-SR Propafenone Generic, Rythmol Quinidine sulfate (83% quinidine base) Generic Quinidine gluconate (62% quinidine base) Generic Quinidine polygalacturonate (60% quinidine base) Cardioquin BETA BLOCKERS LABELED FOR USE AS ANTIARRHYTHMICS Acebutolol Generic, Sectral Esmolol Generic, Brevibloc Propranolol Generic, Inderal CALCIUM CHANNEL BLOCKERS Diltiazem Generic, Cardizem GENERIC NAME AVAILABLE AS ACTION POTENTIAL-PROLONGING AGENTS Amiodarone Generic, Cordarone Dofetilide Tikosyn Dronedarone Multaq Ibutilide Generic, Corvert Sotalol Generic, Betapace Verapamil Generic, Calan, Isoptin MISCELLANEOUS Adenosine Generic, Adenocard Magnesium sulfate Generic DRUGS THAT ACT ON CHLORIDE CHANNELS Ivacaftor (labeled for use in cystic fibrosis) Kalydeco Crofelemer (labeled for use in diarrhea induced by anti-HIV drugs) Fulyzaq PREP AR A TIONS A V AIL ABLE
Antzelevitch C, Burashnikov A: Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin 2011;3:23.
Bezzina CR, Lahrouchi N, Priori SG: Genetics of sudden cardiac death. Circ Res 2015;116:1919.
Burashnikov A, Antzelevitch C: Role of late sodium channel block in the management of atrial fibrillation. Cardiovas Drugs Ther 2013;27:79.
Chinitz JS et al: Rate or rhythm control for atrial fibrillation: Update and controversies. Am J Med 2012;125:1049.
Cho HC, Marban E: Biological therapies for cardiac arrhythmias: Can genes and cells replace drugs and devices? Circ Res 2010;106:674.
Das MK, Zipes DP: Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. J Cardiovasc Pharmacol 2010;55:438.
Duan D: Phenomics of cardiac chloride channels: The systemic study of chloride channel function in the heart. J Physiol 2009;587:2163.
Echt DS et al, for the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781.
El-Sherif N, Boutjdir M: Role of pharmacotherapy in cardiac ion channelopathies. Pharmacol Ther 2015;155:132.
El-Sherif N, Turitto G: Electrolyte disorders and arrhythmogenesis. Cardiol J 2011;18:233.
Fedida D: Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519.
Fuster V et al: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:700.